comparemela.com

Paul Dudley White Award News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Newton resident honored by American Heart Association

Three New Members Join BU s Board of Trustees | BU Today

Ionis Pharmaceuticals (IONS) Names Joseph Loscalzo Chairman, Allene Diaz Appointed Director

Ionis Pharmaceuticals (IONS) Names Joseph Loscalzo Chairman, Allene Diaz Appointed Director
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce

Press release content from Globe Newswire. The AP news staff was not involved in its creation. VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce . Amarin Corporation plcMarch 17, 2021 GMT 28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Award to recognize the authors with the highest ranked abstract from the United States at the International Stroke Conference 2021

VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021

Share: 28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Award to recognize the authors with the highest ranked abstract from the United States at the International Stroke Conference 2021 DUBLIN, Ireland and BRIDGEWATER, N.J., March 17, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT® STROKE at the International Stroke Conference 2021, being held virtually from March 17 – March 19, 2021,

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.